Purpose. We evaluated clinical features and survival outcomes among patients with signet ring and mucinous histologies of colorectal adenocarcinoma by using data from the National Cancer Data Base (NCDB). Methods. Patients aged 18-90 years with colorectal adenocarcinoma diagnosed between 1998 and 2002 were identified from the NCDB. Site-stratified (colon vs. rectum) survival analysis was performed by multivariate relative survival adjusted for multiple clinicopathologic and treatment variables. Results. The study included 244,794 patients: 25,546 (10%) with mucinous, 2,260 (1%) with signet ring, and 216,988 (89%) with nonmucinous, non-signet ring adenocarcinoma. Mucinous and signet ring cancers were more frequently right-sided (60% and 62%, respectively) than were nonmucinous, non-signet ring adenocarcinomas (42%, P \ 0.001). Signet ring histology was associated with a higher stage (P \ 0.001), and 77.2% of signet ring tumors were high-grade lesions, compared with 20% of mucinous and 17% of non-signet ring, nonmucinous adenocarcinomas (P \ 0.001). After adjustment for covariates, signet ring histology was independently associated with higher risk of death [hazard ratio (HR) 1.42, 95% confidence interval (CI) 1.33-1.51, and HR 1.57, CI 1.38-1.77, for tumors located in the colon and rectum, respectively]. Mucinous tumors of the rectum (HR 1.22, CI 1.16-1.29), but not the colon (HR 1.03, CI 1.00-1.06), were associated with increased risk of death. Conclusions. Signet ring cell adenocarcinomas of the colon and rectum and mucinous adenocarcinomas of the rectum are associated with poorer survival. These aggressive histologic variants of colorectal adenocarcinoma should be targeted for research initiatives to improve outcomes.
regarding mucinous histology, which has been associated with younger age at presentation and variable outcomes compared with other adenocarcinomas and is associated with the microsatellite instability pathway. 2, [11] [12] [13] [14] [15] [16] [17] [18] [19] [20] Both histologies are relatively rare, and this contributes to the difficulty of examining clinicopathologic features as well as survival outcomes. It is also unclear whether these features and outcomes differ between primary tumor sites (colon vs. rectum). The purpose of this study was to address these questions by using a large, hospital-based registry of cancer patients in the National Cancer Data Base (NCDB). We hypothesized that signet ring cell and mucinous histologies would more frequently occur in younger patients and at more advanced stages compared with non-signet ring cell, nonmucinous carcinomas. We also hypothesized that signet ring cell tumors would be associated with lower 5-year relative survival, but because of higher association with the microsatellite instability pathway, mucinous histology may be associated with similar or higher 5-year relative survival.
MATERIALS AND METHODS

Data Source
We analyzed data from the NCDB. The NCDB, a joint program of the Commission on Cancer of the American College of Surgeons and the American Cancer Society, serves as a registry of cancer patients at Commission on Cancer-accredited hospitals throughout the United States. Since 1989, the database has captured clinicopathologic, treatment, and outcome information for approximately 70% of the diagnosed cancers in the United States. 21 
Population
We identified all patients aged 18-90 years in the NCDB registry with adenocarcinoma of the colon or rectum according to their International Classification of Disease (ICD) codes (ICD-O-3: C180-8, C209) between the years of 1998 and 2002. By using the ICD-9-O, 3rd edition, coding schema, we then identified patients with the tumor histologic subtypes mucinous (8480, 8481), signet ring cell (8490) and nonmucinous, non-signet ring cell adenocarcinoma (8000, 8010, 8020, 8021, 8140, 8141, 8143, 8144, 8210, 8211, 8220, 8221, 8260, 8261, 8262, 8263).
Patient demographic, tumor, and treatment related characteristics were then evaluated on the basis of comparing their tumor histology and location. Patient related factors included sex, race, age and year of diagnosis. Tumor characteristics included location, stage (AJCC Cancer Staging Manual, 6th edition), and grade. For the purposes of this study, tumors were classified as right colon if they were found in the cecum, ascending colon, or transverse colon, and they were classified as left colon if they were in the descending or sigmoid colon. Well-and moderately differentiated tumors were defined as low grade, whereas poorly or undifferentiated tumors were defined as high grade.
In addition to patient and tumor characteristics, patient treatment characteristics were also included in the analysis. We evaluated receipt of cancer-directed surgery (partial colectomy, subtotal colectomy, total colectomy, or proctocolectomy), the inclusion of chemotherapy and/or radiotherapy, and the sequence of radiotherapy in relation to chemotherapy.
Statistical Analysis
We used v 2 tests to compare categorical baseline demographic and clinical characteristics by histologic subtype. Treatment differences were examined separately for colon and rectal tumors given the different treatment strategies for the two sites. Five-year relative survival was determined from the year of diagnosis by calculating the ratio of observed to expected survival rates of the similar sex-and age-matched U.S. population. 22 Population survival data were obtained from the Human Mortality Database, 1998-2007 (http://www.mortality.org). Relative survival analysis is an established method of performing survival studies that provides an objective measure of survival of cancer patients in the absence of other causes taking into account potential reporting errors in cause of death. 22, 23 It is defined as the ratio of observed survival (all causes of death) amongst a cohort of cancer patients to the expected survival of a comparable cohort of patients without cancer. We determined 5-year relative survival and 95% confidence intervals (CI) according to cancer stage for patients with adenocarcinoma of the colon and rectum separately given the different treatment strategies applied to these tumor locations. To assess the impact of histologic type on relative survival while adjusting for potential covariate influences, we performed multivariate relative survival analysis by generalized linear models assuming Poisson distribution for the observed number of deaths. 24 Covariates adjusted in the regression model were based on their availability in the dataset and their significance in univariate analyses. Models were built separately for colon and rectum to account for the treatment difference in these two distinct cancer sites. All the reported P values were two-sided, and values \ 0.05 were considered statistically significant. All statistical analyses in this report were performed by Stata 11 MP software (StataCorp, College Station, TX).
RESULTS
Patient and Tumor Characteristics
A total of 244,794 cases of colorectal carcinoma were diagnosed between 1998 and 2002 and included for analysis (Table 1) . Most patients (89%) were diagnosed with non-signet ring cell, nonmucinous adenocarcinoma. Signet ring histology was exceedingly rare (1.0%). The distribution of histology was similar in all patients with regard to race and sex, although mucinous tumors were found in more women (54%) than men, unlike the other histologies (P \ 0.0001). For both tumor sites combined, signet ring histology was identified with higher frequency in younger patients than were mucinous and nonmucinous, non-signet ring adenocarcinomas (19% vs. 10% and 10%, respectively, P \ 0.01), and this pattern was also seen when patients were stratified by site ( Table 2 ). For all histologies, rectal cancer was more frequently diagnosed in men (Table 2 ). There was no temporal difference between histologies in terms of number of cases diagnosed per year.
The distribution of sites for primary tumors was similar for nonmucinous, non-signet ring adenocarcinomas (Table 1) . However, most signet ring and mucinous tumors were found in the right colon (62% and 60%, respectively, P \ 0.01). Approximately half of all nonmucinous, nonsignet ring adenocarcinomas were diagnosed early (stage I or II), whereas 80% of signet ring cancers were diagnosed at later stages (III or IV, P \ 0.01). As opposed to mucinous or nonmucinous non-signet adenocarcinomas, most signet ring tumors were high-grade lesions (77%, P \ 0.01).
Treatment Characteristics
Regardless of histology or tumor location, 92-98% of all patients examined received cancer-directed surgery (Table 3) . Chemotherapy was administered to a higher percentage of patients with signet ring or mucinous tumors than patients with nonmucinous, non-signet ring adenocarcinomas (P \ 0.001). Among patients with rectal cancer, those with signet ring or mucinous histology were more likely to undergo radiotherapy than were those with nonmucinous, non-signet ring tumors (P \ 0.001). It should be noted that there is a higher proportion of mucinous and signet ring histology patients with advanced stage disease, which may account for these differences in chemotherapy delivery versus patients with nonmucinous, non-signet ring tumors.
Survival Analysis
Five-year relative survival was determined and stratified by histology, stage, and tumor location (Table 4) . Median follow-up time was 66.8 months (interquartile range 60.2-72.1 months). For both colon and rectal cancers and all histologies, relative survival decreased with increasing stage, with the exception that patients with stage IIIA cancer had higher relative survival than patients with stage II cancer. Signet ring histology was associated with lower relative survival, stage-for-stage, than either mucinous or nonmucinous, non-signet ring adenocarcinomas for both tumor sites. Among patients with tumors in the colon, relative survival for those with mucinous cancers was not different than that for patients with nonmucinous, nonsignet ring adenocarcinomas. However, among patients with rectal cancer, mucinous cancers were associated with lower relative survival than were nonmucinous, non-signet ring adenocarcinomas. 
Multivariate Adjusted Survival Analysis
After adjusting for tumor stage, year of diagnosis, and surgery, we performed a multivariate adjusted relative survival analysis stratified by tumor location (Table 5 ). For patients with either colon or rectal tumors, signet ring histology was associated with a 42-57% higher risk of death compared to nonmucinous, non-signet ring adenocarcinomas (HR 1.42, CI 1.33-1.51, and HR 1.57, CI 1.38-1.77, for tumors of the colon and rectum, respectively). There was a very small but statistically significant increased risk of death associated with mucinous tumors of the colon compared with other histologies (HR 1.03, CI 1.00-1.06). However, among patients with rectal carcinomas, mucinous histology was independently associated with a 22% increased relative risk of death compared with nonmucinous adenocarcinomas (HR 1.22, CI 1.16-1.29).
Multivariate adjusted overall survival analysis results mirror adjusted relative survival multivariate results, with signet ring histology associated with worse survival for both colon (HR 1.31; CI 1.24-1.39) and rectal (HR 1.5; CI 1.34-1.68) tumors compared to nonmucinous, non-signet ring tumors. Similarly mucinous tumors of the colon had a small, but statistically significant increased risk of death overall (HR 1.04; CI 1.02-1.06) compared to nonmucinous, non-signet ring adenocarcinomas. Lastly, rectal mucinous tumors were independently associated with a higher risk of death overall when compared to nonmucinous, non-signet ring histology (HR 1.18; 95% CI 1.13-1.23).
To further illustrate the effect of multiple simultaneous variables on relative survival, we utilized the adjusted model to plot relative survival by histology for patients with tumors of the colon or rectum for years 1 through 5 after resection (Fig. 1) . The adjusted relative survival curves demonstrate the poorer outcomes associated with signet ring histology compared with both mucinous and nonmucinous, non-signet ring adenocarcinomas in either the colon or the rectum. The curves also highlight the increased risk of death associated with mucinous histology compared with nonmucinous, non-signet ring adenocarcinomas for patients with tumors in the rectum but not for patients with tumors in the colon. After adjustment, gender was not associated with a clinically meaningful impact on relative survival for patients with tumors of the colon or rectum. However, African American race was independently associated with increased risk of death for patients with colon or rectal cancers compared with white and other races. High-grade lesions, regardless of tumor site, were associated with worse outcomes for patients compared with lesions of low or unknown grade. The receipt of chemotherapy and radiotherapy were independently associated with higher relative survival compared with not receiving those therapies (Table 5 ).
DISCUSSION
Our analysis identified unique clinicopathologic features and survival outcomes associated with signet ring cell and mucinous colorectal adenocarcinomas as well as site-specific differences in long-term outcomes by using the National Cancer Data Base. Our hypothesis that signet ring cell and mucinous histologies would more frequently occur in younger patients and at more advanced stages compared with non-signet ring, nonmucinous carcinomas was confirmed, as was our hypothesis that signet ring cell tumors would be associated with lower 5-year relative survival. However, we did not find mucinous histology to be associated with higher 5-year relative survival compared with nonmucinous histology.
Signet ring tumors accounted for less than 1% of all reported adenocarcinomas and were more likely to present at a younger age than were non-signet ring adenocarcinomas. Signet ring histology was also associated with a higher grade and more advanced stage at presentation. After adjusting for tumor stage, year of diagnosis, and receipt of adjuvant chemotherapy, signet ring histology was independently associated with poorer outcomes compared with other subtypes of adenocarcinoma regardless of tumor location (Table 5 ). These data reflect the aggressive behavior of signet ring cell adenocarcinomas.
Mucinous tumors were diagnosed 10 times more often than signet ring cell lesions, but they were still much less common than nonmucinous, non-signet ring adenocarcinomas. Mucinous tumors shared many clinicopathologic features with signet carcinomas, including younger age at presentation and more frequent proximal (right colon) location. The higher incidence of stage III and IV disease at presentation suggests most mucinous tumors were probably not associated with the microsatellite instability pathway. Furthermore, despite its historical association with the microsatellite instability pathway and therefore potentially improved outcomes, mucinous histology was not a stageindependent factor affecting survival for patients with colon cancer. After adjusting for tumor stage and year of diagnosis, there was no clinically significant difference in relative survival between mucinous tumors and nonmucinous, non-signet ring adenocarcinomas of the colon (HR 1.03, CI 1.00-1.06) (Table 5 ). Interestingly, we observed that a high relative risk of death was independently associated with mucinous tumors of the rectum (HR 1.22, CI 1.16-1.29). Although our analysis cannot provide insight into a mechanism for this observed difference, it has been reported that mucinous tumors of the rectum may be less likely to respond to neoadjuvant chemoradiation and are linked to poorer disease-specific survival compared with nonmucinous adenocarcinomas. 25 In light of the evidence b a FIG. 1 Model based estimates of relative survival stratified by tumor histology for the colon (a) and rectum (b). In both the colon and rectum, signet ring cell carcinomas had worse relative survival compared to both mucinous and nonmucinous, non-signet ring adenocarcinomas. Mucinous histology was associated with worse relative survival compared to nonmucinous, non-signet ring adenocarcinoma in the rectum only. Non-M nonmucinous, Non-SR non-signet ring regarding the associations between pathologic response to neoadjuvant chemoradiation and survival, our data appear to confirm this observation.
Our analysis has a number of strengths and weaknesses. The NCDB registry covers approximately 70% of all cancer diagnoses in the United States, but there may be underrepresentation of some minorities, such as Hispanics and AsianAmericans. Despite this limitation, the NCDB does allow study of relatively rare pathologies such as is presented in our study, which is the largest to date in the literature. Our study benefits from the large number of reported patients to provide broad insight into the clinicopathologic features and outcomes among these patients. Although specific information regarding disease recurrence was not available, we did perform multivariate adjusted relative survival analysis to estimate the cancer-related mortality while accounting for potential bias from death from other causes or from errors in coding of death certificates about exact cause of death. Relative survival analysis attempts to correct for those biases which are more likely present when using overall survival models for analysis. In spite of having such a large cohort of colorectal cancer patients to facilitate study of less common tumor types, some of the subcohorts within the NCDB are still relatively small, a point that should be considered during subgroup comparisons. However, for the entire cohort, our findings with respect to stage-associated relative survival are consistent with the univariate observed relative survival within Surveillance, Epidemiology, and End Results (e.g., improved survival of stage IIIA patients when compared to stage II) used to validate the changes from the AJCC 6th to 7th editions. 26 Also, this study relies on pathologic review and histologic classification of adenocarcinoma as reported by a variety of independent pathologists. Although definitions of mucinous and signet ring cell histologies have been standardized, variations in interpretation may exist, resulting in misclassification bias for which we cannot account. However, signet ring cells and mucin-producing tumors have relatively distinct features; therefore, this is not likely to represent a significant threat to the analysis. Although the presence of acellular mucin without viable cancer cells among patients with rectal cancer treated with neoadjuvant radiation or chemoradiation has not been associated with adverse outcomes, it is possible that pools of mucin in nonmucinous tumors may have been misinterpreted as mucinous adenocarcinomas. 27, 28 However, acellular mucin is associated with response to neoadjuvant therapy, and therefore this misclassification would have resulted in a decrease in the magnitude of the observed effects. In addition, data regarding microsatellite instability testing are not captured within the NCDB registry, and therefore the impact of this information was not included in our analysis.
In conclusion, our study demonstrates the association between signet ring cell tumors and stage-independent poorer outcomes compared with non-signet ring adenocarcinomas of either the colon or rectum. Mucinous adenocarcinomas are independently associated with poorer outcomes for rectal but not colon cancer patients. These findings mandate routine reporting of these variants in surgical pathologic specimens, and efforts to include them in preoperative biopsies should be made. Counseling of patients may be affected by the knowledge of poorer stagerelated outcomes with these histologic subtypes. This information may also be considered to target patients for novel clinical trials development and explore treatment strategies to improve their outcome.
